Scholars Central

Conference abstractPublished 26 Oct 2016

Spadin and its analogs: A new concept in antidepressant drug design

Authors: Marc Borsotto

Université de Nice Sophia Antipolis, France

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

From the posttranslational maturation process of sortilin, we identified a 17 aminoacid peptide, called spadin as a new antidepressant drug concept. Spadin exerts its antidepressant actions on the TREK-1 potassium channel, a novel antidepressant (AD) target. We showed that spadin acts more rapidly in comparison to other ADs. We have pointed out that spadin induced neurogenesis after only 4-day treatments. We demonstrated that spadin did not display side effects at the cardiac level and on TREK-1 controlled functions such as stroke, epilepsy or pain. With the final goal to make spadin a drug for human clinic, we sought analogs of spadin demonstrating a better affinity or a better in vivo stability or both. By electrophysiology on HEK293 cells stably transfected with TREK-1 channels, several analogs were tested for their ability to block the TREK-1 channel activity. AD effects were measured by using the forced swim and novelty suppressed feeding tests. Synaptogenesis was investigated by measuring the expression level of the synaptic protein PSD-95 in in vitro cultured neurons. Our data allow us to identify a shortened spadin, called mini-spadin, that displayed the same AD properties as spadin and a 400 fold increase in the TREK-1 affinity. Mini-spadin increased the synaptogenesis marker PSD95 levels after only 24 hours of treatment, suggesting that like spadin, mini-spadin was able to induce neurogenesis and synaptogenesis. Even if further experiments are required, the mini-spadin appears to be more efficient than spadin offering a very promising alternate to spadin as human drug.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Marc Borsotto”